Selecta Biosciences, based in Gaithersburg, MD, recently announced a merger with Cartesian Therapeutics, focusing on pioneering mRNA cell therapy for autoimmune diseases. The company is committed to developing potent yet safer cell therapies for patients with autoimmune diseases through their clinical trials and pipeline of therapeutic candidates.
With a team of integrated physicians and scientists, Selecta Biosciences is dedicated to creating the safest and most effective mRNA cell therapies for patients. Cartesian Therapeutics reports full year financial results and provides business updates, with topline data from their phase 2b study of Descartes 08 on track for mid-2024.
Generated from the website